Related Experiment Video
Updated: Aug 13, 2026

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
Published on: April 1, 2022
Landmark trials in endocrine adjuvant therapy for breast carcinoma
1Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA. w-gradishar@northwestern.edu
Abstract:
The review summarizes the outcomes of several landmark trials involving aromatase inhibitors that helped formulate current therapeutic approaches recommended by the American Society of Clinical Oncology for breast carcinoma treatment.
Insights
Aromatase inhibitors are crucial in breast cancer treatment, guiding current American Society of Clinical Oncology recommendations. Landmark trials shaped these therapeutic strategies for breast carcinoma.
Area of Science:
- Oncology
- Pharmacology
Background:
- Breast carcinoma treatment has evolved significantly.
- Hormonal therapies play a key role in managing certain breast cancers.
Purpose of the Study:
- To review landmark clinical trials on aromatase inhibitors.
- To outline their impact on current breast cancer treatment guidelines.
Main Methods:
- Literature review of pivotal studies.
- Analysis of trial outcomes and meta-analyses.
Main Results:
- Aromatase inhibitors demonstrated significant efficacy in multiple trials.
- Established aromatase inhibitors as a cornerstone therapy for hormone receptor-positive breast cancer.
Conclusions:
- Landmark trials have solidified the role of aromatase inhibitors in breast carcinoma management.
- Current therapeutic approaches for breast cancer are informed by these critical research findings.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Endocrine Signaling